All Title Author
Keywords Abstract

Association of a Common Variant at 10q26 and Benign Prostatic Hyperplasia Aggressiveness in Han Chinese Descent

DOI: 10.1155/2013/820849

Full-Text   Cite this paper   Add to My Lib


Recent studies reported that rs2252004 at 10q26 was significantly associated with prostate cancer (PCa) risk in a Japanese population and was subsequently confirmed in a Chinese population. We aimed to assess the relationship between this locus and risk/aggressiveness of benign prostatic hyperplasia (BPH). The current study included 426 BPH cases and 1,008 controls from Xinhua Hospital in Shanghai, China. All BPH patients were treated with α-adrenergic blockers and 5α-reductase inhibitors for at least 9 months. Associations between rs2252004 and BPH risk/aggressiveness were tested using logistic regression. Associations between rs2252004 and clinical parameters including International Prostate Symptom Score (IPSS), total prostate volume (TPV), total PSA (tPSA), and free PSA (fPSA) were evaluated by linear regression. Allele “A” in rs2252004 was significantly associated with increased risk for aggressiveness of BPH in a Chinese population (OR?=?1.42, 95% CI: 1.04–1.96, ). Patients with the genotype “A/A” (homozygous minor allele) had an increase of IPSS and TPV after treatment ( and 0.024, resp.). No association was observed between rs2252004, BPH risk, and baseline clinicopathological traits (All ). Our study is the first to show that rs2252004 at 10q26 was associated with BPH aggressiveness and efficacy of BPH treatment. 1. Introduction Benign prostate hyperplasia (BPH) is an independent disease with clinical symptoms similar to those of carcinoma of the prostrate (PCa), and the prevalence of histologically identifiable BPH is >50% for 60-year-old men and ~90% by age 85 years [1]. While symptomatic BPH is not life threatening, it has a severe impact on the quality of life and requires immediate therapeutic interventions. While studies have shown that BPH causes significant morbidity, the etiology and determinants of severity of this condition remain poorly understood. According to epidemiological studies, 83.3% of PCa are associated with BPH, and 3–20% of patients who have undergone transurethral prostatectomy (TURP) or open prostatectomy for BPH subsequently develop PCa [2]. Although BPH is not considered to be a premalignant lesion or a precursor of PCa, studies have observed anatomic, pathologic, and epidemiological associations and genetic links between PCa and BPH [3]. Over 40 SNPs have been reported to contribute to PCa risk in different ethnicities [4–6]. Fifteen of these SNPs were associated with PCa risk in a Chinese population [7, 8]. The relationship between these SNPs and BPH was recently studied [9, 10]. Three SNPs: rs103294 at LILRA3,


[1]  A. Ziada, M. Rosenblum, and E. D. Crawford, “Benign prostatic hyperplasia: an overview,” Urology, vol. 53, no. 3, pp. 1–6, 1999.
[2]  D. G. Bostwick, W. H. Cooner, L. Denis, G. W. Jones, P. T. Scardino, and G. P. Murphy, “The association of benign prostatic hyperplasia and cancer of the prostate,” Cancer, vol. 70, no. 1, pp. 291–301, 1992.
[3]  A. Alcaraz, P. Hammerer, A. Tubaro, F. H. Schr?der, and R. Castro, “Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review,” European Urology, vol. 55, no. 4, pp. 864–875, 2009.
[4]  J. Xu, J. Sun, and S. L. Zheng, “Prostate cancer risk-associated genetic markers and their potential clinical utility,” Asian Journal of Andrology, vol. 15, no. 3, pp. 314–322, 2013.
[5]  Z. Kote-Jarai, A. A. Olama, G. G. Giles, et al., “Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study,” Nature Genetics, vol. 43, no. 8, pp. 785–791, 2011.
[6]  C. A. Haiman, G. K. Chen, W. J. Blot et al., “Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21,” Nature Genetics, vol. 43, no. 6, pp. 570–573, 2011.
[7]  F. Liu, A. W. Hsing, X. Wang et al., “Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men,” Cancer Science, vol. 102, no. 10, pp. 1916–1920, 2011.
[8]  M. Wang, F. Liu, A. W. Hsing et al., “Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium,” Carcinogenesis, vol. 33, no. 2, pp. 356–360, 2012.
[9]  J. Qi, L. Tian, Z. Chen, et al., “Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population,” Prostate, vol. 73, no. 11, pp. 1182–1190, 2013.
[10]  Y. Jiao, L. Wang, X. Gu, et al., “LILRA3 is associated with benign prostatic hyperplasia risk in a Chinese population,” International Journal of Molecular Sciences, vol. 14, no. 5, pp. 8832–8840, 2013.
[11]  S. Akamatsu, R. Takata, C. A. Haiman et al., “Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese,” Nature Genetics, vol. 44, no. 4, pp. 426–429, 2012.
[12]  J. Xu, Z. Mo, D. Ye, et al., “Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4,” Nature Genetics, vol. 44, no. 11, pp. 1231–1235, 2012.
[13]  S. Mendoza, H. David, G. M. Gaylord, and C. W. Miller, “Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes,” Cancer Genetics and Cytogenetics, vol. 158, no. 2, pp. 142–147, 2005.
[14]  M. Ittmann, “Allelic loss on chromosome 10 in prostate adenocarcinoma,” Cancer Research, vol. 56, no. 9, pp. 2143–2147, 1996.
[15]  Z. Ma, Q. Hu, Z. Chen, et al., “Systematic evaluation of bladder cancer risk-associated single-nucleotide polymorphisms in a Chinese population,” Molecular Carcinogenesis, 2012.
[16]  S. Purcell, B. Neale, K. Todd-Brown et al., “PLINK: a tool set for whole-genome association and population-based linkage analyses,” American Journal of Human Genetics, vol. 81, no. 3, pp. 559–575, 2007.
[17]  J. D. McConnell, C. G. Roehrborn, O. M. Bautista et al., “The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia,” The New England Journal of Medicine, vol. 349, no. 25, pp. 2387–2398, 2003.
[18]  T. J. Shin, C. I. Kim, C. H. Park, B. H. Kim, and Y. K. Kwon, “α-Blocker monotherapy and α-blocker plus 5-Alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results,” Korean Journal of Urology, vol. 53, no. 4, pp. 248–252, 2012.
[19]  A. Singh, “Pharmacogenomics—the potential of genetically guided prescribing,” Australian Family Physician, vol. 36, no. 10, pp. 820–824, 2007.
[20]  X. Gu, R. Na, T. Huang, et al., “SRD5A1 and SRD5A2 are Associated with the Treatment for Benign Prostatic Hyperplasia with the Combination of 5alpha-reductase Inhibitors and alpha-adrenergic-receptor Antagonist,” The Journal of Urology, vol. 2013.
[21]  K. Shibata, A. Hirasawa, N. Moriyama, K. Kawabe, S. Ogawa, and G. Tsujimoto, “α(1a)-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy,” British Journal of Pharmacology, vol. 118, no. 6, pp. 1403–1408, 1996.
[22]  C. A. Mochtar, W. Laan, K. P. Van Houwelingen et al., “Polymorphisms in the α1A-adrenoceptor gene do not modify the short- and long-term efficacy of α1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia,” BJU International, vol. 97, no. 4, pp. 852–855, 2006.
[23]  H.-G. Kim, J.-W. Ahn, I. Kurth et al., “WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome,” American Journal of Human Genetics, vol. 87, no. 4, pp. 465–479, 2010.


comments powered by Disqus